• Product name
    Anti-Osteoprotegerin antibody
    See all Osteoprotegerin primary antibodies
  • Description
    Rabbit polyclonal to Osteoprotegerin
  • Host species
  • Tested applications
    Suitable for: IHC-P, ICC, WB, ELISAmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Highly pure (>98%) recombinant hOPG (human Osteoprotegerin)



Our Abpromise guarantee covers the use of ab9986 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 0.5 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ICC Use at an assay dependent dilution. PubMed: 20513175
WB Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 46 kDa).Can be blocked with Recombinant Human Osteoprotegerin protein (ab110188).
ELISA Use a concentration of 0.5 µg/ml. Allows the detection of 0.2-0.4 ng/well or recombinant hOPG.


  • Function
    Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
  • Tissue specificity
    Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
  • Involvement in disease
    Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
  • Sequence similarities
    Contains 2 death domains.
    Contains 4 TNFR-Cys repeats.
  • Post-translational
    N-glycosylated. Contains sialic acid residues.
    The N-terminus is blocked.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • MGC29565 antibody
    • OCIF antibody
    • OPG antibody
    • Osteoclastogenesis inhibitory factor antibody
    • Osteoprotegerin antibody
    • PDB5 antibody
    • TNF receptor superfamily member 11b antibody
    • TNFRSF 11B antibody
    • TNFRSF11B antibody
    • TR 1 antibody
    • TR1 antibody
    • TR11B_HUMAN antibody
    • Tumor necrosis factor receptor superfamily member 11B antibody
    see all


  • ab9986 staining Osteoprotegerin in human skin tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with PBS + 1% BSA + 5% NGS for 30 minutes at 20°C. Samples were incubated with primary antibody (1/20) for 9 hours at 4°C. ab7090, a HRP-conjugated goat anti-rabbit IgG polyclonal (1/300) was used as the secondary antibody.

    See Abreview

  • All lanes : Anti-Osteoprotegerin antibody (ab9986) at 1 µg/ml

    Lane 1 : U2OS (Human osteosarcoma cell line) Whole Cell Lysate
    Lane 2 : HEK293 (Human embryonic kidney cell line) Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 46 kDa
    Observed band size: 56 kDa (why is the actual band size different from the predicted?)
    Additional bands at: 32 kDa. We are unsure as to the identity of these extra bands.

    Exposure time: 150 seconds

    Osteoprotegerin contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
  • ab9986 at 0.5 µg/ml  staining human breast invasive ductal carcinoma by IHC-P. The antibody was incubated overnight incubation at 4˚C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 Sodium Citrate buffer is recommended. 


This product has been referenced in:
  • Vaziri-Sani F  et al. Osteoprotegerin autoantibodies do not predict low bone mineral density in middle-aged women. Bone Rep 7:132-136 (2017). Read more (PubMed: 29124083) »
  • Mediero A  et al. Adenosine A2A receptor activation prevents wear particle-induced osteolysis. Sci Transl Med 4:135ra65 (2012). IHC-P ; Mouse . Read more (PubMed: 22623741) »

See all 3 Publications for this product

Customer reviews and Q&As

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step
(agent) for 30 minute(s) · Concentration: 100% · Temperature: 20°C
Antigen retrieval step
Human Tissue sections (skin)

Abcam user community

Verified customer

Submitted Mar 24 2014

Thank you for contacting us. Unfortunately both anti-Osteoprotegerin antibody ab18051 and ab9986 have not as yet been assessed for their neutralising activity to our knowledge. This does not mean that these will not work as a neutralising antibodie...

Read More

On a Western it should migrate at approximately 20kD.

Approx. 140-150kDa


Sign up